{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:13:47Z","timestamp":1788369227239,"version":"build-2803163510"},"reference-count":50,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:00:00Z","timestamp":1788048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100018127","name":"CaaMTech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018127","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018637","name":"College of Health Sciences, University of Wyoming","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018637","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012417","name":"College of Veterinary Medicine and Biomedical Sciences, Colorado State University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012417","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Fentanyl is the leading cause of fatal overdoses worldwide, and repeated use may lead to substance use disorder (SUD). In SUD, drug-associated contexts can trigger reward-related behavior even in the absence of the drug. Psychedelic compounds may weaken context-drug associations, reducing reward-related behavior to fentanyl.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>We evaluated the effects of the psychedelic psilocin and its derivatives, 4-MeO-MiPT and 4-HO-MiPT, on fentanyl-induced conditioned place preference (CPP) in male and female C57BL\/6J mice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Mice were conditioned to distinct fentanyl and saline control contexts, then assessed for fentanyl place preference before and after treatment with one of the test compounds. Anxiety-related side effects of each compound were evaluated using an elevated plus maze (EPM) model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Psilocin reduced fentanyl CPP exclusively in females, 4-MeO-MiPT in both sexes, and 4-HO-MiPT had no effect. None of the compounds significantly altered anxiety-like behaviors in EPM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>These findings support further preclinical investigations of the sex-dependent effects of psilocin and 4-MeO-MiPT on fentanyl reward behavior.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02698811261478613","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T06:39:46Z","timestamp":1788158386000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Differential effects of psilocybin derivatives on fentanyl-induced conditioned place preference in male and female mice"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9689-3550","authenticated-orcid":false,"given":"Tiffini N.","family":"Lovell","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences, Colorado State University, Fort Collins, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1375-990X","authenticated-orcid":false,"given":"Peter B.","family":"James","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Wyoming, Laramie, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5420-9174","authenticated-orcid":false,"given":"Skylar L.","family":"Hodgins","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Wyoming, Laramie, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Johnson Noya","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Wyoming, Laramie, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Arner","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Wyoming, Laramie, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4273-1237","authenticated-orcid":false,"given":"Ana-Clara","family":"Bobadilla","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Colorado State University, Fort Collins, USA"},{"name":"School of Pharmacy, University of Wyoming, Laramie, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,30]]},"reference":[{"key":"e_1_3_3_2_1","unstructured":"American Psychiatric Association (2022) Opioid Use Disorder. Available at: https:\/\/www.psychiatry.org:443\/patients-families\/opioid-use-disorder"},{"key":"e_1_3_3_3_1","doi-asserted-by":"crossref","unstructured":"Bardo MT Neisewander JL Kelly TH (2013) Individual differences and social influences on the neurobehavioral pharmacology of abused drugs. Pharmacological Reviews 65(1): 255\u2013290. https:\/\/doi.org\/10.1124\/pr.111.005124","DOI":"10.1124\/pr.111.005124"},{"key":"e_1_3_3_4_1","doi-asserted-by":"crossref","unstructured":"Bardo MT Rowlett JK Harris MJ (1995) Conditioned place preference using opiate and stimulant drugs: A meta-analysis. Neuroscience & Biobehavioral Reviews 19(1): 39\u201351. https:\/\/doi.org\/10.1016\/0149-7634(94)00021-R","DOI":"10.1016\/0149-7634(94)00021-R"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.115.011163"},{"key":"e_1_3_3_6_1","doi-asserted-by":"crossref","unstructured":"Benvenuti F Colombo D Soverchia L et al. (2023) Psilocybin prevents reinstatement of alcohol seeking by disrupting the reconsolidation of alcohol-related memories. Psychopharmacology 240(7): 1521\u20131530. https:\/\/doi.org\/10.1007\/s00213-023-06384-w","DOI":"10.1007\/s00213-023-06384-w"},{"key":"e_1_3_3_7_1","doi-asserted-by":"crossref","unstructured":"Cabeza De Vaca S Carr KD (1998) Food restriction enhances the central rewarding effect of abused drugs. The Journal of Neuroscience 18(18): 7502\u20137510. https:\/\/doi.org\/10.1523\/JNEUROSCI.18-18-07502.1998","DOI":"10.1523\/JNEUROSCI.18-18-07502.1998"},{"key":"e_1_3_3_8_1","doi-asserted-by":"crossref","unstructured":"Cameron LP Patel SD Vargas MV et al. (2023) 5-HT2ARs mediate therapeutic behavioral effects of psychedelic tryptamines. ACS Chemical Neuroscience 14(3): 351\u2013358. https:\/\/doi.org\/10.1021\/acschemneuro.2c00718","DOI":"10.1021\/acschemneuro.2c00718"},{"key":"e_1_3_3_9_1","doi-asserted-by":"crossref","unstructured":"Cameron LP Tombari RJ Lu J et al. (2021) A non-hallucinogenic psychedelic analogue with therapeutic potential. Nature 589(7842): 474\u2013479. https:\/\/doi.org\/10.1038\/s41586-020-3008-z","DOI":"10.1038\/s41586-020-3008-z"},{"key":"e_1_3_3_10_1","doi-asserted-by":"crossref","unstructured":"Carhart-Harris RL Goodwin GM (2017) The therapeutic potential of psychedelic drugs: Past present and future. Neuropsychopharmacology 42(11): 2105\u20132113. https:\/\/doi.org\/10.1038\/npp.2017.84","DOI":"10.1038\/npp.2017.84"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1107\/S2056989020002923"},{"key":"e_1_3_3_12_1","doi-asserted-by":"crossref","unstructured":"Dever JA Hertz MF Dunlap LJ et al. (2024) The medications for opioid use disorder study: Methods and initial outcomes from an 18-month study of patients in treatment for opioid use disorder. Public Health Reports 139(4): 484\u2013493. https:\/\/doi.org\/10.1177\/00333549231222479","DOI":"10.1177\/00333549231222479"},{"key":"e_1_3_3_13_1","doi-asserted-by":"crossref","unstructured":"Floris G Dabrowski KR Zanda MT et al. (2025) Psilocybin reduces heroin seeking behavior and modulates inflammatory gene expression in the nucleus accumbens and prefrontal cortex of male rats. Molecular Psychiatry 30(5): 1801\u20131816. https:\/\/doi.org\/10.1038\/s41380-024-02788-y","DOI":"10.1038\/s41380-024-02788-y"},{"key":"e_1_3_3_14_1","doi-asserted-by":"crossref","unstructured":"Fonseca FRD Navarro M (1998) Role of the limbic system in dependence on drugs. Annals of Medicine 30(4): 397\u2013405. https:\/\/doi.org\/10.3109\/07853899809029940","DOI":"10.3109\/07853899809029940"},{"key":"e_1_3_3_15_1","doi-asserted-by":"crossref","unstructured":"Garnett MF Mini\u00f1o AM (2024) Drug Overdose Deaths in the United States 2003-2023. NCHS Data Briefs 522 19 December. NationalVital Statistics System. Available at: https:\/\/stacks.cdc.gov\/view\/cdc\/170565","DOI":"10.15620\/cdc\/170565"},{"key":"e_1_3_3_16_1","doi-asserted-by":"crossref","unstructured":"Glatfelter GC Schalk SS Walther D et al. (2026) Serotonin transporter blockade reduces the psychedelic-like effects of 4-methoxy- N -methyl- N -isopropyltryptamine and related analogs. ACS Chemical Neuroscience 17(12): 2348\u20132363. https:\/\/doi.org\/10.1021\/acschemneuro.6c00083","DOI":"10.1021\/acschemneuro.6c00083"},{"key":"e_1_3_3_17_1","doi-asserted-by":"crossref","unstructured":"Gukasyan N Davis AK Barrett FS et al. (2022) Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. Journal of Psychopharmacology 36(2): 151\u2013158. https:\/\/doi.org\/10.1177\/02698811211073759","DOI":"10.1177\/02698811211073759"},{"key":"e_1_3_3_18_1","doi-asserted-by":"crossref","unstructured":"Halberstadt AL Geyer MA (2013) Characterization of the head-twitch response induced by hallucinogens in mice: Detection of the behavior based on the dynamics of head movement. Psychopharmacology 227(4): 727\u2013739. https:\/\/doi.org\/10.1007\/s00213-013-3006-z","DOI":"10.1007\/s00213-013-3006-z"},{"key":"e_1_3_3_19_1","doi-asserted-by":"crossref","unstructured":"Halberstadt AL Koedood L Powell SB et al. (2011) Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice. Journal of Psychopharmacology 25(11): 1548\u20131561. https:\/\/doi.org\/10.1177\/0269881110388326","DOI":"10.1177\/0269881110388326"},{"key":"e_1_3_3_20_1","doi-asserted-by":"crossref","unstructured":"Jaster AM Hadlock TM Buzzi B et al. (2025) Sex-specific role of the 5-HT2A receptor in psilocybin-induced extinction of opioid reward. Nature Communications 16(1): 10206. https:\/\/doi.org\/10.1038\/s41467-025-64887-w","DOI":"10.1038\/s41467-025-64887-w"},{"key":"e_1_3_3_21_1","doi-asserted-by":"crossref","unstructured":"Johnson M Richards W Griffiths R (2008) Human hallucinogen research: Guidelines for safety. Journal of Psychopharmacology 22(6): 603\u2013620. https:\/\/doi.org\/10.1177\/0269881108093587","DOI":"10.1177\/0269881108093587"},{"key":"e_1_3_3_22_1","doi-asserted-by":"crossref","unstructured":"Kopra EI Ferris JA Winstock AR et al. (2022) Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms. Journal of Psychopharmacology 36(8): 965\u2013973. https:\/\/doi.org\/10.1177\/02698811221084063","DOI":"10.1177\/02698811221084063"},{"key":"e_1_3_3_23_1","doi-asserted-by":"crossref","unstructured":"Kozell LB Eshleman AJ Swanson TL et al. (2023) Pharmacologic activity of substituted tryptamines at 5-hydroxytryptamine (5-HT)2A receptor (5-HT2AR) 5-HT2CR 5-HT1AR and serotonin transporter. The Journal of Pharmacology and Experimental Therapeutics 385(1): 62\u201375. https:\/\/doi.org\/10.1124\/jpet.122.001454","DOI":"10.1124\/jpet.122.001454"},{"key":"e_1_3_3_24_1","doi-asserted-by":"crossref","unstructured":"Kwan AC Olson DE Preller KH et al. (2022) The neural basis of psychedelic action. Nature neuroscience 25(11): 1407\u20131419. https:\/\/doi.org\/10.1038\/s41593-022-01177-4","DOI":"10.1038\/s41593-022-01177-4"},{"key":"e_1_3_3_25_1","doi-asserted-by":"crossref","unstructured":"Lai HMX Cleary M Sitharthan T et al. (2015) Prevalence of comorbid substance use anxiety and mood disorders in epidemiological surveys 1990\u20132014: A systematic review and meta-analysis. Drug and Alcohol Dependence 154: 1\u201313. https:\/\/doi.org\/10.1016\/j.drugalcdep.2015.05.031","DOI":"10.1016\/j.drugalcdep.2015.05.031"},{"key":"e_1_3_3_26_1","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Gim\u00e9nez JF Gonz\u00e1lez-Maeso J (2017) Hallucinogens and serotonin 5-HT2A receptor-mediated signaling pathways. In: Halberstadt AL Vollenweider FX Nichols DE (eds) Behavioral Neurobiology of Psychedelic Drugs. Current Topics in Behavioral Neurosciences. Springer pp.45\u201373. Available at: https:\/\/link.springer.com\/10.1007\/7854_2017_478","DOI":"10.1007\/7854_2017_478"},{"key":"e_1_3_3_27_1","doi-asserted-by":"crossref","unstructured":"Ludbrook J (1998) Multiple comparison procedures updated. Clinical and Experimental Pharmacology and Physiology 25(12): 1032\u20131037. https:\/\/doi.org\/10.1111\/j.1440-1681.1998.tb02179.x","DOI":"10.1111\/j.1440-1681.1998.tb02179.x"},{"key":"e_1_3_3_28_1","doi-asserted-by":"crossref","unstructured":"Martin D Delgado A Calu D (2024) The psychedelic DOI increases dopamine release in nucleus accumbens to predictable rewards and reward cues. bioRxiv. Available at: https:\/\/www.biorxiv.org\/content\/10.1101\/2024.03.29.587390v1 (accessed 3 September 2024).","DOI":"10.1101\/2024.03.29.587390"},{"key":"e_1_3_3_29_1","doi-asserted-by":"crossref","unstructured":"McGriff SA Hecker JC Maitland AD et al. (2025) Psychedelic-like effects induced by 2 5-dimethoxy-4-iodoamphetamine lysergic acid diethylamide and psilocybin in male and female C57BL\/6J mice. Psychopharmacology 242(10) 2249\u20132260. https:\/\/doi.org\/10.1007\/s00213-025-06795-x","DOI":"10.1007\/s00213-025-06795-x"},{"key":"e_1_3_3_30_1","doi-asserted-by":"crossref","unstructured":"McHugh RK Votaw VR Sugarman DE et al. (2018) Sex and gender differences in substance use disorders. Clinical Psychology Review 66: 12\u201323. https:\/\/doi.org\/10.1007\/s00213-025-06795-x","DOI":"10.1016\/j.cpr.2017.10.012"},{"key":"e_1_3_3_31_1","doi-asserted-by":"crossref","unstructured":"McKendrick G Graziane NM (2020) Drug-induced conditioned place preference and its practical use in substance use disorder research. Frontiers in Behavioral Neuroscience 14: 582147. https:\/\/doi.org\/10.3389\/fnbeh.2020.582147","DOI":"10.3389\/fnbeh.2020.582147"},{"key":"e_1_3_3_32_1","unstructured":"National Institute on Drug Abuse (2025) Fentanyl DrugFacts. Available at: https:\/\/nida.nih.gov\/publications\/drugfacts\/fentanyl"},{"key":"e_1_3_3_33_1","unstructured":"National Institute on Drug Abuse National Institutes of Health and U.S. Department of Health and Human Services (2023) Medications for Opioid Overdose Withdrawal & Addiction. Available at: https:\/\/nida.nih.gov\/research-topics\/opioids\/medications-opioid-overdose-withdrawal-addiction-infographic"},{"key":"e_1_3_3_34_1","doi-asserted-by":"crossref","unstructured":"Ottenbacher KJ (1991) Interpretation of interaction in factorial analysis of variance design. Statistics in Medicine 10(10): 1565\u20131571. https:\/\/doi.org\/10.1002\/sim.4780111014","DOI":"10.1002\/sim.4780101008"},{"key":"e_1_3_3_35_1","doi-asserted-by":"crossref","unstructured":"Pulido-Saavedra A Oliva HNP Prudente TP et al. (2025) Effects of psychedelics on opioid use disorder: A scoping review of preclinical studies. Cellular and Molecular Life Sciences 82(1): 49. https:\/\/doi.org\/10.1007\/s00018-024-05519-2","DOI":"10.1007\/s00018-024-05519-2"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1137\/S0036144501357233"},{"key":"e_1_3_3_37_1","doi-asserted-by":"crossref","unstructured":"Richetto J Polesel M Weber-Stadlbauer U (2019) Effects of light and dark phase testing on the investigation of behavioural paradigms in mice: Relevance for behavioural neuroscience. Pharmacology Biochemistry and Behavior 178: 19\u201329. https:\/\/doi.org\/10.1016\/j.pbb.2018.05.011","DOI":"10.1016\/j.pbb.2018.05.011"},{"key":"e_1_3_3_38_1","doi-asserted-by":"crossref","unstructured":"Rodgers RJ Dalvi A (1997) Anxiety defence and the elevated plus-maze. Neuroscience & Biobehavioral Reviews 21(6): 801\u2013810. https:\/\/doi.org\/10.1016\/S0149-7634(96)00058-9","DOI":"10.1016\/S0149-7634(96)00058-9"},{"key":"e_1_3_3_39_1","doi-asserted-by":"crossref","unstructured":"Rootman JM Kryskow P Harvey K et al. (2021) Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers. Scientific Reports 11(1): 22479. https:\/\/doi.org\/10.1038\/s41598-021-01811-4","DOI":"10.1038\/s41598-021-01811-4"},{"key":"e_1_3_3_40_1","doi-asserted-by":"crossref","unstructured":"Rybaczyk LA Bashaw MJ Pathak DR et al. (2005) An overlooked connection: Serotonergic mediation of estrogen-related physiology and pathology. BMC Women\u2019s Health 5(1): 12. https:\/\/doi.org\/10.1186\/1472-6874-5-12","DOI":"10.1186\/1472-6874-5-12"},{"key":"e_1_3_3_41_1","doi-asserted-by":"crossref","unstructured":"Schlag AK Aday J Salam I et al. (2022) Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. Journal of Psychopharmacology 36(3): 258\u2013272. https:\/\/doi.org\/10.1177\/02698811211069100","DOI":"10.1177\/02698811211069100"},{"key":"e_1_3_3_42_1","doi-asserted-by":"crossref","unstructured":"Shadani S Conn K Andrews ZB et al. (2024) Potential differences in psychedelic actions based on biological sex. Endocrinology 165(8): bqae083. https:\/\/doi.org\/10.1210\/endocr\/bqae083","DOI":"10.1210\/endocr\/bqae083"},{"key":"e_1_3_3_43_1","doi-asserted-by":"crossref","unstructured":"Studerus E Gamma A Kometer M et al. (2012) Prediction of psilocybin response in healthy volunteers. PLoS ONE 7(2): e30800. https:\/\/doi.org\/10.1371\/journal.pone.0030800","DOI":"10.1371\/journal.pone.0030800"},{"key":"e_1_3_3_44_1","unstructured":"Substance Abuse and Mental Health Services Administration and Office of the Surgeon General (2016) Facing Addiction in America: The Surgeon General\u2019s Report on Alcohol Drugs and Health. US Department of Health and Human Services: 413. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK424857\/"},{"key":"e_1_3_3_45_1","doi-asserted-by":"crossref","unstructured":"Van Der Meer PB Fuentes JJ Kaptein AA et al. (2023) Therapeutic effect of psilocybin in addiction: A systematic review. Frontiers in Psychiatry 14: 1134454. https:\/\/doi.org\/10.3389\/fpsyt.2023.1134454","DOI":"10.3389\/fpsyt.2023.1134454"},{"key":"e_1_3_3_46_1","doi-asserted-by":"crossref","unstructured":"Vargas MV Dunlap LE Dong C et al. (2023) Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors. Science 379(6633): 700\u2013706. https:\/\/doi.org\/10.1126\/science.adf0435","DOI":"10.1126\/science.adf0435"},{"key":"e_1_3_3_47_1","doi-asserted-by":"crossref","unstructured":"Villamil VI Underwood N Cremer LJ et al. (2024) Barriers to retention in medications for opioid use disorder treatment in real-world practice. Journal of Substance Use and Addiction Treatment 160: 209310. https:\/\/doi.org\/10.1016\/j.josat.2024.209310","DOI":"10.1016\/j.josat.2024.209310"},{"key":"e_1_3_3_48_1","doi-asserted-by":"crossref","unstructured":"Volkow ND Blanco C (2023) Fentanyl and other opioid use disorders: Treatment and research needs. American Journal of Psychiatry 180(6): 410\u2013417. https:\/\/doi.org\/10.1176\/appi.ajp.20230273","DOI":"10.1176\/appi.ajp.20230273"},{"key":"e_1_3_3_49_1","doi-asserted-by":"crossref","unstructured":"Walf AA Frye CA (2007) The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. Nature Protocols 2(2): 322\u2013328. https:\/\/doi.org\/10.1038\/nprot.2007.44","DOI":"10.1038\/nprot.2007.44"},{"key":"e_1_3_3_50_1","doi-asserted-by":"crossref","unstructured":"Zafar R Siegel M Harding R et al. (2023) Psychedelic therapy in the treatment of addiction: The past present and future. Frontiers in Psychiatry 14: 1183740. https:\/\/doi.org\/10.3389\/fpsyt.2023.1183740","DOI":"10.3389\/fpsyt.2023.1183740"},{"key":"e_1_3_3_51_1","doi-asserted-by":"crossref","unstructured":"Zhang G Stackman RW (2015) The role of serotonin 5-HT2A receptors in memory and cognition. Frontiers in Pharmacology 6: 225. https:\/\/doi.org\/10.3389\/fphar.2015.00225","DOI":"10.3389\/fphar.2015.00225"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811261478613","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811261478613","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811261478613","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T16:24:57Z","timestamp":1788366297000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811261478613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,30]]},"references-count":50,"alternative-id":["10.1177\/02698811261478613"],"URL":"https:\/\/doi.org\/10.1177\/02698811261478613","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,30]]},"article-number":"02698811261478613"}}